Regeneron Pharmaceuticals (NASDAQ:REGN) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Earnings and Valuation
This table compares Regeneron Pharmaceuticals and OPKO Health's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Regeneron Pharmaceuticals | $7.86 billion | 6.98 | $2.12 billion | $21.47 | 23.94 |
| OPKO Health | $901.90 million | 3.07 | $-314,920,000.00 | ($0.41) | -10.07 |
Regeneron Pharmaceuticals has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Regeneron Pharmaceuticals and OPKO Health's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Regeneron Pharmaceuticals | 37.30% | 26.71% | 19.39% |
| OPKO Health | -20.69% | -7.96% | -5.51% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Regeneron Pharmaceuticals and OPKO Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Regeneron Pharmaceuticals | 0 | 10 | 13 | 1 | 2.63 |
| OPKO Health | 0 | 0 | 2 | 0 | 3.00 |
Regeneron Pharmaceuticals presently has a consensus target price of $628.52, suggesting a potential upside of 22.27%. OPKO Health has a consensus target price of $7.00, suggesting a potential upside of 69.49%. Given OPKO Health's stronger consensus rating and higher possible upside, analysts plainly believe OPKO Health is more favorable than Regeneron Pharmaceuticals.
Institutional and Insider Ownership
85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 29.1% of OPKO Health shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 40.9% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility and Risk
Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
Summary
Regeneron Pharmaceuticals beats OPKO Health on 11 of the 15 factors compared between the two stocks.
